Back to Services
S4b
Precision Oncology
Genetic risk -> screening -> medication -> MRD -> neoantigen
VUS triple-model scoring, traditional methods only label "variant of uncertain significance". Full-loop analysis.
1-3 weeks5K-30K/personCapability Coverage 80%
Pipeline Flow
End-to-end dry-computing loop
1
Variant Annotation
ANNOVAR + ClinVar multi-source annotation
2
Pathogenicity Scoring
VUS triple-model cross-scoring
3
Pharmacogenomics
PharmGKB drug-gene associations
4
MRD Monitoring
Minimal residual disease dynamic tracking
5
Neoantigen Prediction
NetMHCpan predicts tumor neoantigens
6
Full-loop Report
Integrated delivery
Core Tools
ANNOVARClinVarPharmGKBESMFoldDLKcatMHCflurryNetMHCpan
Core Advantages
VUS Triple-model Scoring
Structure + enzyme activity + MHC three models cross-judge pathogenicity
Chinese Population Optimization
Genos trained on 636 Chinese population pan-genomes
Full Loop
From genetic risk to MRD monitoring end-to-end tracking
Capability Coverage
80%Pipeline Synergy
Start Your Project Precision Oncology
Start with just 1 project, no team needed.